https://doi.org/10.1038/s41398-026-04325-7

Depression, affecting hundreds of millions worldwide, manifests through complex neurobiological mechanisms, many of which remain poorly understood. Among these, the role of neuroinflammation and immune activation within the central nervous system has increasingly garnered attention. Microglia, the resident immune cells of the brain, play a pivotal role in maintaining neural homeostasis but can become detrimental when hyperactivated. Pyroptosis, a form of programmed cell death associated with inflammation, is one such pathway wherein activated microglia release inflammatory cytokines leading to neuronal dysfunction. The selective inhibition of this process represents a promising therapeutic avenue the current study explores with remarkable precision.

Tomentosin, a natural sesquiterpene lactone derived from the medicinal plant Artemisia, has been traditionarily recognized for its anti-inflammatory and anti-cancer properties. However, its neurological effects have remained elusive until this recent exploration within a sophisticated network-based therapeutic framework. Researchers employed integrative computational models combined with experimental validation to uncover tomentosin’s unique capacity to modulate pyroptotic signaling selectively within microglia, thereby attenuating neuroinflammation without broadly suppressing immune function.

This study’s innovative approach is rooted in network pharmacology, which enables the mapping of multifaceted molecular interactions between bioactive compounds and the human proteome. Through this lens, tomentosin was identified as a potent modulator of key pyroptotic regulators, including caspase-1 and gasdermin D. By inhibiting the cleavage and activation of gasdermin D, tomentosin effectively blocks the formation of membrane pores that facilitate the release of pro-inflammatory interleukins such as IL-1β and IL-18. This precise mechanism interrupts the feed-forward loop of chronic neuroinflammation observed in fluoxetine-resistant depression.

In fluoxetine-resistant individuals, standard selective serotonin reuptake inhibitors (SSRIs) fail to yield therapeutic benefits, often due to persistent neuroinflammatory states that SSRIs cannot address. By targeting microglial pyroptosis, tomentosin addresses a fundamental pathological process overlooked by conventional antidepressants. The research team demonstrated that administration of tomentosin in preclinical models resulted in significant amelioration of depressive-like behaviors otherwise unresponsive to fluoxetine, underscoring its potential as a game-changing agent in psychiatric medicine.

Furthermore, the study provides compelling evidence that tomentosin’s action is both selective and safe. Notably, systemic immune function remained intact in experimental subjects, highlighting tomentosin’s ability to discriminate between pathological and physiological inflammatory processes. This specificity reduces the risk of immunosuppression, a common side effect of many anti-inflammatory treatments, and positions tomentosin as a uniquely favorable candidate for clinical translation.

The implications of selectively targeting pyroptosis extend beyond depression. Pyroptosis is increasingly implicated in a spectrum of neurodegenerative and neuropsychiatric disorders characterized by chronic inflammation, such as Alzheimer’s disease and multiple sclerosis. The elucidation of tomentosin’s mechanism invites broader investigation into its utility as a therapeutic scaffold for multiple brain diseases unified by inflammatory pathology.

This study also exemplifies the power of integrating multi-omic datasets and network pharmacology to uncover subtle, yet clinically significant molecular targets hidden within complex biological systems. By bridging computational predictions with in vivo validation, the research beautifully navigates the translational gap that often impedes novel drug discovery in neuropsychiatry, offering a replicable model for future breakthroughs.

Critically, the research underscores the importance of investigating non-neuronal cellular contributors to psychiatric illnesses. The centrality of microglia in mediating neuroinflammatory processes that precipitate or exacerbate depressive symptoms prompts a paradigm shift away from purely neuronal-focused therapeutics. Tomentosin’s ability to mitigate microglial dysfunction sets a precedent for developing treatments that precisely recalibrate the brain’s immune milieu.

In summary, the discovery of tomentosin’s targeted inhibition of microglial pyroptosis lays a promising foundation for addressing fluoxetine-resistant depression — a formidable challenge in psychiatric care. Through elegant network-based strategies and rigorous experimentation, this study elevates our understanding of depression pathophysiology and opens new therapeutic horizons grounded in immunomodulation. As the field progresses, tomentosin may well emerge as a cornerstone of next-generation antidepressant regimens, catalyzing improved outcomes for patients who have long faced therapeutic dead ends.

Recognizing the broader significance, future research avenues will likely explore optimal delivery methods, potential synergistic combinations with existing antidepressants, and longitudinal effects of tomentosin treatment. Clinical trials to evaluate safety and efficacy in human populations are an eagerly anticipated next step. The integration of precision medicine principles tailoring tomentosin-based therapies to specific neuroinflammatory profiles represents an exciting frontier following these preclinical successes.

Moreover, the study highlights the untapped potential of plant-derived compounds in neuropharmacology. Tomentosin exemplifies how traditional medicine-inspired molecules can be repurposed through modern scientific rigor to address contemporary health crises. This fusion of ethnobotanical knowledge with cutting-edge computational biology could accelerate the discovery of similarly transformative therapies across diverse neuropsychiatric and neurodegenerative conditions.

In conclusion, this landmark research not only propels tomentosin into the spotlight as a selective modulator of pyroptotic microglial death but also redefines the therapeutic landscape of pharmacoresistant depression with its sophisticated network-based discovery approach. It invites a reevaluation of current treatment paradigms, emphasizing a nuanced immunological perspective in mental health disorders and fostering hope for millions affected by refractory depression globally.

Subject of Research:
Tomentosin’s selective targeting of microglial pyroptosis as a therapeutic strategy to overcome fluoxetine-resistant depression.

Article Title:
Tomentosin selectively targets microglial pyroptosis to overcome fluoxetine-resistant depression: a network-based therapeutic discovery.

Article References:
Lee, JS., Kang, JY., Lee, WY. et al. Tomentosin selectively targets microglial pyroptosis to overcome fluoxetine-resistant depression: a network-based therapeutic discovery. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04092-5

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41398-026-04092-5

Ischemic stroke, characterized by an abrupt obstruction of blood flow to parts of the brain, provokes catastrophic neuronal damage due to oxygen and nutrient deprivation. The ensuing inflammatory response engages microglia as frontline responders. While these cells play essential roles in tissue repair and debris clearance, their metabolic state dictates their functional behavior. Until recently, we understood little about the biochemical underpinnings that modulate microglial activity during ischemic injury. This pioneering research illuminates TPI1’s pivotal role in coordinating mitochondrial architecture to recalibrate microglial metabolism, offering an unprecedented glimpse into the molecular choreography governing brain immune responses.

At the molecular core of this discovery lies TPI1, an enzyme traditionally recognized as a glycolytic catalyst responsible for interconverting triose phosphates during carbohydrate metabolism. Remarkably, Zhang and colleagues identified that beyond its canonical metabolic role, TPI1 localizes to the inner mitochondrial membrane where it mediates extensive remodeling of mitochondrial cristae— the infolded structures vital for optimizing mitochondrial function and oxidative phosphorylation. Using advanced electron microscopy coupled with metabolic flux assays, the team demonstrated that TPI1’s modulation of cristae ultrastructure enhances mitochondrial efficiency, facilitating a metabolic switch that supports microglia’s heightened energy demands during ischemic stress.

The study intricately details how TPI1-driven cristae remodeling orchestrates a shift in microglial cellular metabolism from primarily glycolytic to a hybrid state that incorporates oxidative phosphorylation. This metabolic rewiring underpins a functional reprogramming of microglia, enabling them to sustain prolonged activation and effectively execute neuroprotective functions. By fine-tuning mitochondrial architecture, TPI1 acts as a molecular rheostat, aligning metabolic outputs with cellular immune requirements. The implications extend broadly, suggesting that targeting mitochondrial structural dynamics may offer novel avenues to modulate immune cell metabolism in various neurodegenerative conditions.

Crucially, the research employed state-of-the-art in vivo ischemic stroke models alongside sophisticated in vitro assays with primary microglial cultures. Conditional knockout studies abrogating TPI1 expression underscored its indispensable role; microglia lacking TPI1 exhibited disrupted cristae morphology, diminished oxidative capacity, and impaired neuroprotective responses post-ischemia. Rescue experiments, restoring TPI1 function, reversed these deficits, reinforcing the enzyme’s unique contribution to microglial immunometabolic adaptation. These findings are a testament to the power of integrating genetic tools with ultrastructural and metabolic analyses in deciphering complex cellular phenomena.

Beyond molecular mechanistics, this work delineates TPI1’s role in governing microglial inflammatory phenotypes. Metabolic shifts elicited by cristae remodeling were closely tied to the cells’ cytokine secretion profiles, phagocytic activities, and reactive oxygen species production. Enhanced mitochondrial function enabled microglia to mount calibrated inflammatory responses, balancing tissue clearance with the promotion of neuronal survival. By facilitating this metabolic plasticity, TPI1 emerges as a master regulator at the nexus of metabolism and immune function, with profound implications for mitigating the secondary damage that often follows ischemic stroke.

The elucidation of TPI1’s noncanonical function challenges historic paradigms that positioned glycolytic enzymes solely within cytosolic metabolic pathways. Discovering TPI1 as a structural organizer of mitochondrial cristae introduces a transformative perspective on how metabolic enzymes moonlight as architectural modulators, dynamically tuning organelle morphology to environmental cues. This dual functionality signifies a new conceptual framework where enzymatic activity and sub-organelle organization intertwine to sculpt cellular responses, heralding a new dimension in cellular bioenergetics research.

Methodologically, the study leveraged cutting-edge cryo-electron tomography to capture native mitochondrial cristae with nanometer resolution, revealing how TPI1 influences membrane curvature and density. Complementary super-resolution fluorescence microscopy mapped TPI1’s spatial distribution within mitochondria under ischemic conditions. Integrating these imaging modalities with metabolic flux measurements provided a holistic view linking ultrastructure with function. Such technical sophistication underscores the transformative potential of multimodal approaches in exploring the dynamic interplay between cell metabolism, organelle morphology, and immune behavior.

From a therapeutic standpoint, the insights into TPI1-mediated mitochondrial remodeling open enticing prospects. Pharmacological agents or gene therapy interventions that enhance TPI1 function or mimic its effects on mitochondrial ultrastructure could strategically reprogram microglial metabolism, optimizing their reparative capacity post-stroke. Such strategies might circumvent the pitfalls of broadly suppressing inflammation by instead reorienting immune metabolism toward resolution and regeneration. The work paves the way for precision-medicine approaches targeting cellular energetics as an adjunct to conventional stroke treatments.

The discovery also resonates with emerging concepts linking mitochondrial dysfunction to neurodegenerative diseases such as Alzheimer’s and Parkinson’s, conditions marked by chronic inflammation and impaired microglial function. By elucidating how mitochondrial ultrastructure influences immune cell metabolism, this study offers mechanistic clues potentially translatable to broader neuropathologies. Understanding TPI1’s role may guide novel interventions beyond stroke, addressing fundamental bioenergetic disturbances underlying a spectrum of brain disorders.

The broader scientific community has lauded this research for its elegance and conceptual boldness. By uniting mitochondrial biology, immunometabolism, and neurobiology, it epitomizes multidisciplinary innovation. The findings invigorate ongoing debates about the plasticity of cellular metabolism in immune cells and illustrate how subtle organelle remodeling can dictate cell fate and function. This integrative perspective is set to fuel myriad future studies exploring metabolic control points in diverse physiological and pathological contexts.

Moreover, this study encourages re-examination of other glycolytic enzymes as potential modulators of mitochondrial structure and function. The revelation that a traditionally cytosolic enzyme reshapes mitochondrial cristae suggests a hidden repertoire of multifunctional proteins in metabolic organelles awaiting discovery. This reinvigorates interest in metabolic moonlighting phenomena and enhances our appreciation of cellular complexity and adaptability at the molecular level.

In summary, Zhang, Ye, Wang, and colleagues articulate a compelling narrative linking TPI1 enzyme activity to mitochondrial ultrastructure remodeling in microglia, galvanizing a metabolic shift essential for mounting effective immunological defenses against ischemic stroke. Their work delineates a sophisticated molecular mechanism uniting metabolism, organelle architecture, and immune regulation, with transformative implications for neurological disease treatment. As ischemic stroke remains a leading cause of morbidity and mortality worldwide, these insights herald a promising frontier toward metabolic interventions that harness innate immune functions for neuroprotection and regeneration.

This landmark research, by meticulously unraveling the crosstalk between microglial metabolism and mitochondrial morphology, not only advances fundamental cell biology but also charts an innovative trajectory for translational therapeutics. Targeting TPI1 and its cristae remodeling axis could redefine strategies to temper neuroinflammation and enhance neural repair. As such, this study stands as a testament to the power of molecular insight in forging new paths against devastating brain injuries.

Subject of Research: The study focuses on the role of triose phosphate isomerase 1 (TPI1) in remodeling mitochondrial cristae ultrastructure to rewire microglial immunometabolism in response to ischemic stroke.

Article Title: Triose phosphate isomerase 1 remodels mitochondrial cristae ultrastructure to rewire microglial immunometabolism against ischemic stroke.

Article References:
Zhang, XW., Ye, XM., Wang, R. et al. Triose phosphate isomerase 1 remodels mitochondrial cristae ultrastructure to rewire microglial immunometabolism against ischemic stroke. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72779-w

Image Credits: AI Generated